<DOC>
	<DOC>NCT00791557</DOC>
	<brief_summary>Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.</brief_summary>
	<brief_title>Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Must Be ages 1875 Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum Must never have received Infliximab for the treatment of pyoderma gangrenosum Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments. Have a history of serious infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>